BIOGRAFT, INC.

Stanford, CA · Medtech · Private

External biodegradable scaffold device to prevent saphenous vein graft failure after coronary artery bypass surgery

Grants
$345K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery$345,103
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
678LumiraDx Ltd—$682M
679ADVANCED VASCULAR THERAPIES, INC.——
680STARK STREET MATERIALS COMPANY——
681BIOGRAFT, INC.——
682ZIMMER BIOMET HOLDINGS, INC.—$216M
683NUMENTUS TECHNOLOGIES INC——
684ECATE LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Vascular Graft Assemblies, Vascular Graft Systems, And Methods Of Use Thereofapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.